Payment overview · 2025
General Payments
$67,897.24
269 reported records · 18 companies
Healthcare provider profile · identity verified
Gus Theodos, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SAINT LOUIS, MO · NPI 1053401422
Verified facts
What the public records show
CMS Open Payments records show Gus Theodos, M.D. received $67,897.24 in general payments during 2025 across 269 reported records.
Edwards Lifesciences Corporation accounted for 67.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $45,960.28 | 67.7% | 135 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16,977.63 | 25.0% | 35 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,300.34 | 1.9% | 9 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $915.37 | 1.4% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $860.92 | 1.3% | 27 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $750.01 | 1.1% | 9 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $462.59 | 0.7% | 25 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $170.02 | 0.2% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $109.80 | 0.2% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $92.10 | 0.1% | 4 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $78.76 | 0.1% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$54.62 | 0.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $36.34 | 0.1% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $33.26 | 0.1% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $30.15 | 0.0% | 2 | 2025 |
| LANTHEUS MEDICAL IMAGING, INC. | Unresolved — no canonical attribution shown | $28.73 | 0.0% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $18.67 | 0.0% | 1 | 2025 |
| ZOLL Circulation Inc | Unresolved — no canonical attribution shown | $17.65 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $36,250.00 | 8 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,000.00 | 3 |
| Food and Beverage | $9,206.38 | 235 |
| Travel and Lodging | $6,940.86 | 22 |
| Honoraria | $500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $15,998.21 | 34 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $15,919.09 | 4 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $14,775.82 | 10 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $8,257.43 | 6 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $2,193.07 | 22 | 2025 |
Source payment records
|
|||||
| TENDYNE Normalized: tendyne |
Device | Abbott Laboratories | $933.04 | 3 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $716.21 | 13 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $659.73 | 13 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $659.08 | 5 | 2025 |
Source payment records
|
|||||
| MANTA Normalized: manta |
Device | Teleflex LLC | $566.67 | 4 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $462.59 | 25 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $280.76 | 14 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $256.29 | 2 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $204.98 | 2 | 2025 |
Source payment records
|
|||||
| Orsiro Mission Normalized: orsiro mission |
Device | BIOTRONIK INC. | $170.02 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $158.22 | 2 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $125.31 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $109.80 | 1 | 2025 |
Source payment records
|
|||||
| ACUSON Origin Diagnostic Ultrasound System Normalized: acuson origin diagnostic ultrasound system |
Device | Siemens Medical Solutions USA, Inc. | $78.76 | 5 | 2025 |
Source payment records
|
|||||
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $70.14 | 3 | 2025 |
Source payment records
|
|||||
| Comet Normalized: comet |
Device | Boston Scientific Corporation | $43.56 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $34.88 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $30.15 | 2 | 2025 |
Source payment records
|
|||||
| DEFINITY Normalized: definity |
Drug | LANTHEUS MEDICAL IMAGING, INC. | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Catheter Normalized: catheter |
Device | ZOLL Circulation Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Downstream Cartridge Normalized: downstream cartridge |
Device | ZOLL Circulation Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| TherOx DS2 Console Normalized: therox ds2 console |
Device | ZOLL Circulation Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $9.73 | 2 | 2025 |
Source payment records
|
|||||
| VSI Normalized: vsi |
Device | Teleflex LLC | $5.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 428 | 149 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 217 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 60 |
| Eliquis | Apixaban | 176 | 40 |
| Furosemide | Furosemide | 121 | 33 |
| Brilinta | Ticagrelor | 116 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 34 |
| Carvedilol | Carvedilol | 88 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 81 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 35 |
| Losartan Potassium | Losartan Potassium | 77 | 27 |
| Lisinopril | Lisinopril | 75 | 25 |
| Repatha Sureclick | Evolocumab | 61 | 11 |
| Entresto | Sacubitril/Valsartan | 59 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 13 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 15 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Prednisone | Prednisone | 19 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $67,897.24 · 269 records | Edwards Lifesciences Corporation | ACUSON Origin Diagnostic Ultrasound System, AMPLATZER AMULET, AVVIGO Guidance System, Asahi Coronary Wires, Asahi Peripheral Vascular Wires, Barostim Neo System, CARDIVA VASCADE MVP XL VVCS 10-12F, CLEVIPREX, COREVALVE EVOLUT R, Catheter, Comet, DEFINITY, Downstream Cartridge, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EVOQUE, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FFRct, GUIDELINER, General - Vascular Access, Indigo System, KENGREAL, LifeVest, MANTA, MITRACLIP, NAVITOR, Orsiro Mission, PASCAL, ROTAPRO, SAPIEN 3 Ultra RESILIA, SAVVYWIRE, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TENDYNE, TRICLIP, TherOx DS2 Console, VSI, WATCHMAN Access System | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error